Clinical Trial Update: Eslicarbazepine Acetate (BIA 2 093) as Therapy for Refractory Partial Seizures in Children [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating eslicarbazepine acetate (BIA 2 093) for refractory partial seizures in children; trial completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Partial Epilepsy in Children and Adolescents

Drugs mentioned

• eslicarbazepine acetate (eslicarbazepine acetate)

Snippet

Sponsor: Bial - Portela C S.A. | Conditions: Partial Epilepsy in Children and Adolescents | Phase 3 | Status: COMPLETED | Results posted: 2014-07-17